Repository logo

Browsing by Issue Date, starting with "2017-02-09"

Filter results by year or month
Now showing 1 - 2 of 2
  • A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND)
    Publication . Figueira, J; Henriques, J; Amaro, M; Rosas, V; Alves, D; Cunha-Vaz, J
    PURPOSE: The aim of this study was to assess the effectiveness and safety of ILUVIEN® in patients with chronic diabetic macular edema (DME) who were insufficiently responsive to prior therapies. METHODS: This is a prospective, nonrandomized, multicenter, open-label, phase 4 pilot study assessing the effectiveness and safety of ILUVIEN® involving 12 patients insufficiently responsive to available therapies. Assessments were performed at screening, baseline, week 1, and months 1, 3, 6, 9, and 12. Demographics, medical/ophthalmic history, prior laser, anti-VEGF, and steroid treatments, and lab tests were recorded at screening. A complete ophthalmic examination and SD-OCT were performed at screening and at all follow-up visits. RESULTS: The patients showed improvements in best-corrected visual acuity (+3.7 letters), with greater improvement among pseudophakic patients (+6.8 letters) compared with phakic patients (-2.5 letters) 12 months after ILUVIEN®. The mean central subfield thickness decrease from baseline to month 12 was statistically significant, with a rapid reduction in the first week. Regarding safety, only 2 patients showed an intraocular pressure (IOP) increase over 25 mm Hg during the study, and the rise in IOP was well managed with eye drops only. CONCLUSIONS: This prospective and pilot study suggests that ILUVIEN® is safe and may be considered effective for chronic DME patients insufficiently responsive to other available therapies as it showed a rapid and sustained improvement of macular edema obtained after treatment with ILUVIEN®.
    2017-02-09Journal article Open access Show more
  • Search for heavy resonances decaying to tau lepton pairs in proton-proton collisions at $ \sqrt{s}=13 $ TeV
    Publication . CMS collaboration (2282 authors); Calpas, Betty; Nayak, Aruna; Bargassa, Pedrame; Beirão Da Cruz E Silva, Cristóvão; Di Francesco, Agostino; Faccioli, Pietro; Ferreira Parracho, Pedro Guilherme; Gallinaro, Michele; Hollar, Jonathan; Leonardo, Nuno; Lloret Iglesias, Lara; Rodrigues Antunes, Joao; Seixas, Joao; Toldaiev, Oleksii; Vadruccio, Daniele; Varela, Joao; Vischia, Pietro; David Tinoco Mendes, Andre; Silva, Pedro; Musella, Pasquale; Pela, Joao
    A search for heavy resonances that decay to tau lepton pairs is performed using proton-proton collisions at $\sqrt{s} = 13$ TeV. The data were collected with the CMS detector at the CERN LHC and correspond to an integrated luminosity of 2.2 inverse femtobarns. The observations are in agreement with standard model predictions. An upper limit at 95% confidence level on the product of the production cross section and branching fraction into tau lepton pairs is calculated as a function of the resonance mass. For the sequential standard model, the presence of Z' bosons decaying into tau lepton pairs is excluded for Z' masses below 2.1 TeV, extending previous limits for this final state. For the topcolor-assisted technicolor model, which predicts Z bosons that preferentially couple to third-generation fermions, Z' masses below 1.7 TeV are excluded, representing the most stringent limit to date.
    2017-02-09Journal article Open access Show more